Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The frustrating thing with this stock is whenever there is good news (as we had recently) the increase in the stock price is de minimis. However, whenever there is the hint of bad news, the stock price falls through the floor.
When is the red blood cell treatment going to be ready for FDA approval? There has been far too many delays on this and right now this stock needs to show profits (forget about narrowing losses). Also, any news if this company is the target of a merger or takeover?
I am long on this stock and will continue to hold - but it is frustrating that good news does not seem to move the stock up - and the slightest amount of bad news brings the price down precipitously.
This company needs to start generating profits - sooner rather than later - and the only thing that will move them toward profitability is getting their red blood cell treatment approved by the FDA. Any time frame for getting this accomplished? If this is not done soon, we may be at a depressed stock price for many years into the future.
I am long on this stock. While I know they report decent to good quarterly results on a consistent basis and I believe that Hoch's buy back plan as a drag on the stock price has been a little overstated, there is something about this stock not readily apparent that is keeping it at such a low level.
I am hopeful the second quarter results exceed expectations. If this is a buyout target, it would nice to see the stock price between $3 and $5 per share before an offer to purchase is made.
Like many on the board, I initially thought the buy out price was a little low (I was looking for $35 to $40 ps) but a 59% premium is nothing to sneeze at.
My question does not focus on another potential bidder but on the large short position that existed with this stock just before the buyout. Given the sudden increase in price, would this not create a short squeeze and potentially drive the price up in the short term, thus allowing those who expected a higher buy out price to sell their shares before the buyout is finalized? I guess my question is what happens to those people who had a short position - don't they have to cover before the buyout occurs?
I am long on the stock. However, I have been disappointed many times - just when the stock seems to be gaining traction, it gets "disappointing" news with the quarterly report and the stock takes a significant hit.
For this rally to continue, I believe that the 8/4 quarterly report has to at least meet Wall Street expectations - otherwise, the price may drop back to the high 5's lower 6's.
As to the Zika Virus, I wonder if this (combined with a recent report from a pennystock "newsletter") is artificially inflating the stock price. A good second quarter result would bolster some confidence in this stock starting a consistent run higher (perhaps it may trigger the short squeeze a lot of us have been waiting for).
Finally, it would be nice to get FDA approval for red blood cells - then the full potential of the product could be realized.
But what is causing the rise????
Also, let's not get too excited - remember, we were at $8.00 about a year ago.
What makes you say this? One of the (many) frustrating aspects of owning this stock is when the price goes up, there is no news or explanation for the price spike (when it goes down, it is because it has failed to meet earnings estimates).
What is it with this stock? Good product, good technology, Baker Brothers had been loading up on the stock last year - but several misses on street estimates and we have a stock that has lost over half its value in the course of one calendar year.
It would be welcome if the Officers or Board of Directors would provide some guidance as to when they could expect to meet or exceed the street's estimates (or dare I say turn a profit). I know that prior FDA decisions have caused a drag on the stock - but still....
Full disclosure - I am long on the stock and not looking to sell (yet)...
While I agree the Company's plans, marketing and sales initiatives are "spot on", at some point the Company has to meet the street's expectations. I know that there are costs involved in marketing and getting FDA approval - but the results released today can only be described as disappointing.
I agree with the posts that say a slow steady growth in stock price is better for the stock in the long run. However, this stock, despite consistent good news for the last year or so has been consistently inconsistent in terms of stock price performance.
Slow steady growth means that the price of the stock goes up slowly, but noticeably over time. Having the stock go to $0.16 before retreating to $0.14 then going up to $0.155 before going down to $0.138 and then holding around $0.1475 is not an example of slow steady growth.
Such an inconsistent performance by the stock has me wondering if we are getting the whole story from the CEO and management....
If these numbers represent the "whole story", then I agree with CEO Long's statement that the company is undervalued (I would have said woefully undervalued).
I agree there is a shot to get to $.20 on Monday - but with numbers like these, the stock price should continue to increase steadily -
If it slides back to $0.10 - $0.12, it would be most disappointing and frankly give rise to a lot of questions about the health of the company and the veracity of the statements made by the CEO...
With that said, 3Q numbers (on their face) are very good news.
Missed again on estimates and a revision downward for yearly revenues. I am long on this stock and am not looking to sell, but at some point, the company needs to at least meet expectations - every time this stock seems to gain some traction, the company releases disappointing results which in turn drives the price down again.
I want to clarify my previous post:
I believe that Mermelstein is correct that the selling by Hoch (one of the key insiders of the company) "should not" impact the stock price negatively. When an insider has a 10(b)5-1 trading plan as part of his "package", it is not necessarily a bad thing - nor is it a sign of a lack of faith in the company as the sales must be made in compliance with the plan.
WITH THAT SAID, JaneyH and numerous others are correct that the mere existence of the plan and the fact that each and every sale is announced to the Public (as required by law) drives away potential investors (individuals as well as institutional) because any sale of stock by an insider will be viewed as negative.
The company should address this issue head on. It is clearly having an effect on the stock price. A full disclosure of all the particulars of the plan is not necessary - however, perhaps discussing why the plan was established for Mr. Hoch and identifying the annual number of shares to be sold pursuant to the plan will calm some concerns by potential investors.
FYI - I am also long with a substantial position and am not looking to sell anytime soon.
I believe that Mermelstein is correct on the theory (Hoch's selling is preapproved and preplanned and as such should not have a large impact the stock price).
However, the reality of the situation seems to support the statements of JaneyH and those who criticize Hoch's continuous selling.
No matter how you present the case and no matter what the reason, many investors (especially institutional investors) will shy away from a stock if an insider is selling shares - especially if such sales are at regular intervals.
This company is legitimately making a profit, cash flow is good to very good and it is in an industry where successful smaller businesses are taken over by larger competitors. All of this should be affecting the stock in a much more positive way. It is great that the stock is at a 52 week high - but it should be higher than $0.15. The huge headwind that the stock price faces is the insider selling.
Why is this stock tanking? Very disappointing...
The product is good but the stock performance is very disappointing.
The product is good but the stock performance is very disappointing.
Lots of positive news and a close at $0.14 on 10/17. What will be the catalyst to get this stock to take off??? Positive movement has been frustratingly slow on this...
I am long on this stock - and I like the product, technology and its potential impact medically. I only wish I shared the same optimism as Mogman - the price of the stock is extremely volatile (which is not totally unexpected) and it seems the slightest hint of bad news impacts the stock price drastically. If it gets to $100.00 per share, that would be great - however, I would like to see it get back to $8.00 and sustain that as the "floor" for a while.
Your response concerning ebola is well taken - however, the performance of this stock has been, at best, frustrating. There was a run up to $8.00 per share earlier this year, but after some slightly disappointing news in the 2nd quarter, the price dropped below $4.00 per share. Additionally, FDA "approval" keeps getting pushed back (now were expecting it in 1st quarter 2015).
News about the company and the product and technology it is developing has been in general consistently good - but this has not translated into the share prices increasing - and I find myself wondering why this is...
I have tried the Lobster Bisque and two other soups. I do not agree with the reviewers who gave the product one star. I did not find the soups salty - they did have a considerable amount of black pepper that was a little "overpowering", nor did I have the gastric distress discussed by one of the reviewers. The criticisms that might keep people from buying the product (and keep the stock price down) are: the cost for one box of soup is almost double than the cost of the canned soups, there is a lack of flavors (I have only seen four offered) and despite statements to the contrary, the product is not offered in as many locations as you would think.
It would be nice to see the product advertised on TV - I think a commercial using the actor who played the "Soup Nazi" would get people to go out and try the product.
Advertising a company's services is not de facto participating in a pump and dump scheme. If the company has a product or service that is generating profits but seems to be "flying under the radar", it would behoove the company to engage in a legitimate publicity campaign.
I am a little surprised at the lack of movement in this stock after three quarters of consistently good news. Unlike others who have posted, I am not so concerned about insiders trading within the parameters of their 10b5-1 plans (although given that this is a (very) smallcap stock the point raised by some that insiders should refrain from selling until the stock price gains some traction is well taken).
Since there has been nothing but good news recently and the forecast is for even greater results, the lack of upward movement on the stock price is not only disappointing, but also a cause for some concern (FYI: I am long on the stock and do not intend to sell - yet).
It would seem to me that if the picture is as rosy as most are painting it, the company would do well to invest some of its profits in PR and get the word out to both the business and investment communities.
This stock has me puzzled - I have tried several of their soups - all of them are very good (although a little on the spicy side). The product is prominently displayed in the supermarkets and the soup seem to sell. However, the stock price has steadily declined over the last year. What will it take to reverse this trend?
Excellent product and technology being developed; favorable second quarter results; progress being made on all fronts in terms of having their products approved by the FDA and the stock price lags - badly. Very long on this stock - but it is getting very frustrating with a consistently deflated stock price.
Believe me, I am hanging in there - been in this too long not to hang in. And I know that small biotech companies are subject to wild fluctuations. However, when a stock drops from $8.00 to $3.50 in the span of a few months and the news concerning the company is positive, in general, it causes a person to scratch their head and become concerned.
Even if the 2nd quarter numbers are good, the reporting on the results usually accentuates the portion of the earnings report that did not "meet expectations". It seems that the stock price is unusually susceptible to "minor" disappointing news driving the price down. Again, head scratching and a point for concern...
What is happening with this stock??? A few months ago, this stock traded at around $8.00 per share. It has since lost over half of its value and the news surrounding the stock has been, in general, positive.
I am long on this stock and I believe the product once approved by the FDA (for platelets, plasma and hopefully red blood cells) will impact the stock positively. But how long is this going to take??